Home Ingredients Huperzine A
Cognitive

Huperzine A

Huperzia serrata
Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Huperzine A is a sesquiterpene alkaloid isolated from Chinese club moss (Huperzia serrata) — used in Traditional Chinese Medicine for centuries as 'qian ceng ta'. Distinguished by being a potent, selective, reversible acetylcholinesterase inhibitor — same fundamental mechanism as Alzheimer's drugs (donepezil, rivastigmine). Used in China as prescription drug for Alzheimer's; sold as supplement in US for cognitive support. Critical: drug-like potency at supplemental doses; warrants similar caution to prescription AChE inhibitors.

Studied Dose 50-200 mcg twice daily (100-400 mcg/day total); China research uses up to 400 mcg/day for Alzheimer's
Active Compound Huperzine A (sesquiterpene alkaloid)

Benefits

Alzheimer's Disease Cognitive Improvement

Multiple Chinese trials show huperzine A 200-400 mcg/day improves cognitive function in mild-moderate Alzheimer's. meta-analysis (20 RCTs) confirmed cognitive benefits comparable to standard prescription AChE inhibitors. Used as prescription drug in China; supplement status in US.

Supported by Trial 1

Cognitive Function in Healthy Adults / MCI

Some evidence for cognitive enhancement in healthy adults and mild cognitive impairment. Effect modest but consistent with mechanism.

Supported by Trial 2

Memory Enhancement

Memory benefits documented in Alzheimer's trials and some healthy adult studies. Mechanism: increased acetylcholine availability supports memory consolidation.

Supported by Trial 2, Trial 1

Vascular Dementia Adjunct

Some evidence in vascular dementia and post-stroke cognitive impairment. Used in China for these indications.

Supported by Trial 2, Trial 1

Theoretical Neuroprotection

Animal studies show neuroprotective effects beyond AChE inhibition — antioxidant, anti-inflammatory, NMDA receptor modulation. Clinical translation incomplete.

Supported by Trial 1

Mechanism of action

1

Selective, Reversible Acetylcholinesterase Inhibition

Huperzine A is a potent, selective, reversible inhibitor of acetylcholinesterase (AChE) — the enzyme that degrades acetylcholine at synapses. Increased synaptic acetylcholine availability — same fundamental mechanism as Alzheimer's drugs donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl). Higher selectivity for AChE over butyrylcholinesterase than some prescription AChE inhibitors.

2

NMDA Receptor Modulation

Huperzine A also modestly modulates NMDA glutamate receptors — additional neuroprotective mechanism. May reduce excitotoxicity.

3

Antioxidant / Anti-Inflammatory

Animal studies show antioxidant and anti-inflammatory effects in brain — additional mechanisms beyond cholinesterase inhibition.

4

Long Half-Life

Plasma half-life ~12-14 hours; longer than many natural compounds; allows twice-daily dosing for sustained effect.

Clinical trials

1
Huperzine A for Alzheimer's

Pooled analysis of 20 clinical trials of huperzine A in Alzheimer's disease.

Pooled across 20 Alzheimer's clinical trials.

Significant improvements in cognitive function (MMSE), activities of daily living, behavior. Effect comparable to standard AChE inhibitors. Established huperzine A as evidence-based AD treatment in China.

2
Huperzine A for MCI — Smaller Trials

Smaller trials of huperzine A in mild cognitive impairment and healthy adults.

MCI patients and healthy adults.

Modest cognitive improvements. Less robust evidence than for Alzheimer's specifically. Mechanism plausible.

Side effects and drug interactions

Common Potential side effects

Cholinergic side effects — same as prescription AChE inhibitors:
GI distress (nausea, vomiting, diarrhea) — most common; usually dose-limiting.
Bradycardia (slow heart rate).
Hypersalivation.
Lacrimation (excessive tearing).
Increased sweating.
Insomnia / vivid dreams.
Muscle cramping / fasciculations.
Bronchospasm in asthmatics.
Urinary urgency.
Cardiac arrhythmias rare.

Important Drug interactions

Anticholinergic medications — opposing mechanism; drugs that should be reviewed: oxybutynin (overactive bladder), trihexyphenidyl, scopolamine, atropine, diphenhydramine (Benadryl), older antidepressants (amitriptyline, nortriptyline), antipsychotics (chlorpromazine, olanzapine).
Prescription cholinesterase inhibitors (donepezil, rivastigmine, galantamine) — additive; avoid combination; risk of severe cholinergic toxicity.
Beta-blockers — additive bradycardia; monitor heart rate.
Cardiac medications — bradycardia concerns; monitor.
Pyridostigmine, neostigmine (myasthenia gravis drugs) — additive; avoid without medical supervision.
Asthma medications — bronchospasm risk; consult.
Pre-surgery — discontinue 2 weeks before due to anesthesia interactions.
Pregnancy/lactation — limited safety data; avoid.

More Cognitive Ingredients

Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a patented curcumin extract developed by Verdure Sciences using SLCP™ (Solid…
Cognitive
CurQfen® (Curcumin-Fenugreek FenuMat — Akay Bioactives)
CurQfen® is a patented curcumin complex from Curcuma longa rhizomes formulated with FENUMA…
Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an adaptogenic herb from Ayurvedic tradition, widely u…

Frequently asked questions about Huperzine A

What is huperzine A?

Huperzine A is a compound from Chinese club moss (Huperzia serrata) that slows the breakdown of acetylcholine, a key memory neurotransmitter. It is studied for memory and cognitive support, including in age-related decline.

What is huperzine A used for?

It is most studied for supporting memory and cognition, with some trials in Alzheimer's disease and age-related memory concerns. By slowing acetylcholine breakdown, it is thought to support learning and recall.

How much huperzine A should I take?

Studies commonly use very small amounts, around 50 to 200 mcg (micrograms, not milligrams) per day. It is often cycled rather than taken continuously because of its long-lasting action. Follow product labeling.

Is huperzine A safe?

At low doses it is generally tolerated, but because it acts on the acetylcholine system, it can cause nausea, sweating, or, at higher doses, more significant effects, and it can interact with certain medications. Use cautiously and check with a doctor, especially if on cholinergic or Alzheimer's drugs.

What is the recommended dosage of Huperzine A?

The clinically studied dose is 50-200 mcg twice daily (100-400 mcg/day total); China research uses up to 400 mcg/day for Alzheimer's Always follow the product label and check with a healthcare provider for personal advice.

Is Huperzine A safe, and does it have side effects?

For most healthy adults, Huperzine A is well tolerated at studied doses. Reported effects can include: Cholinergic side effects — same as prescription AChE inhibitors: GI distress (nausea, vomiting, diarrhea) — most common; usually dose-limiting. It may also interact with some medications. Huperzine A is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Huperzine A interact with any medications?

Possible interactions include: Anticholinergic medications — opposing mechanism; drugs that should be reviewed: oxybutynin (overactive bladder), trihexyphenidyl, scopolamine, atropine, diphenhydramine (Benadryl), older antidepressants (amitriptyline, nortriptyline), antipsychotics (chlorpromazine, olanzapine). If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Huperzine A?

NutraSmarts rates the evidence for Huperzine A as Moderate (3 out of 5). It is backed by 2 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389-94..PubMedUsed to support: Phase II randomized trial of huperzine A in mild-to-moderate Alzheimer disease.